AIM: To see the effect of intravitreal Ranibizumab in Epiretinal membrane(ERM). METHODOLOGY: 12 patients were selected in our study and intravitreal Ranibizumab(0.5 mg) was injected to respective eye of each patient for 3 consecutive doses at 1 month interval after prior informed consent and instituitional clearance. Best corrected visual acuity(BCVA) and intraocular pressure(IOP) measurement along with detailed fundal evaluation under mydriasis by using 78D,90D lens,indirect ophthalmoscopy and central macular thickness measurement by spectral domain optical coherence tomography(SD–OCT) were performed both before intervention and after intervention at 1 month interval upto 6 months after last injection in both eyes. Central macular thickness reduction more than 100 microns from baseline value after 6 months of last injection was considered as clinically significant. The data were then analysed by paired t test using SPSS software. RESULTS: Out of 12 patients, 7 had shown reduction in membrane thickness as evidenced by central macular thickness reduction of more than 100 microns after 6 months of last injection from baseline value. CONCLUSION: Intravitreal Ranibizumab can be a handy tool in the management of epiretinal membreane but can not replace pars plana vitrectomy(PPV) as first choice therapy.